Mostrar registro simples

dc.contributor.authorCunha, Viviane Roseli dapt_BR
dc.contributor.authorBrenol, Claiton Viegaspt_BR
dc.contributor.authorBrenol, João Carlos Tavarespt_BR
dc.contributor.authorXavier, Ricardo Machadopt_BR
dc.date.accessioned2013-01-16T01:39:54Zpt_BR
dc.date.issued2011pt_BR
dc.identifier.issn0482-5004pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/62550pt_BR
dc.description.abstractNos ultimos 20 anos, tem sido demonstrado que a artrite reumatoide (AR) pode reduzir a expectativa de vida de 3 a 10 anos em comparacao com a populacao em geral. Atualmente, a doenca cardiovascular (DCV) e a principal causa de morte nos pacientes com AR, e a ocorrencia de infarto agudo do miocardio pode ser ate quatro vezes maior nesses pacientes. A resposta infl amatoria sistemica de etiologia autoimune, somada a presenca de sindrome metabolica (SM), torna duas vezes maior o risco de DCV fatal ou nao fatal e da aterosclerose coronariana, independentemente da idade e sexo. A artrite reumatoide tem sido associada a aumento da prevalencia de SM, mas o papel das diferentes caracteristicas da doenca, tais como a duracao da doenca, atividade e tratamento com glucocorticoides nao estao bem definidos. O objetivo deste trabalho e revisar a prevalencia de SM e os fatores implicados no desenvolvimento de aterosclerose nos pacientes com AR, avaliando os aspectos clinicos da AR e sua associacao com o desenvolvimento de SM.pt_BR
dc.description.abstractIn the past 20 years, the life expectancy of patients with rheumatoid arthritis (RA) has been shown to be reduced by three to ten years as compared to that of the general population. Currently, cardiovascular disease (CVD) is the major cause of death in patients with RA, and acute myocardial infarction can be up to four times more frequent in these patients. The autoimmune systemic infl ammatory response, along with the presence of metabolic syndrome (MetS), doubles the risk for fatal or non-fatal CVD and coronary atherosclerosis, regardless of age and sex. Rheumatoid arthritis has been associated with increased prevalence of MetS, but its role in the different characteristics of the disease, such as disease duration, activity, and treatment with glucocorticoids, is not well defi ned. This study aimed at reviewing the prevalence of MetS and the factors implicated in the development of atherosclerosis in RA patients, assessing the clinical aspects of RA and its association with the development of MetS.en
dc.format.mimetypeapplication/pdf
dc.language.isoporpt_BR
dc.relation.ispartofRevista brasileira de reumatologia. Campinas. Vol. 51, n. 3 (2011), p. 260-268pt_BR
dc.rightsOpen Accessen
dc.subjectMetabolic syndrome Xen
dc.subjectSíndrome metabólicapt_BR
dc.subjectRheumatoid arthritisen
dc.subjectArtrite reumatóidept_BR
dc.subjectCardiovascular diseasesen
dc.subjectDoenças cardiovascularespt_BR
dc.titleArtrite reumatoide e síndrome metabólicapt_BR
dc.title.alternativeRheumatoid arthritis and metabolic syndrome en
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000795257pt_BR
dc.type.originNacionalpt_BR


Thumbnail
Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples